|
Acquisitions (Details) (USD $)
|
1 Months Ended |
3 Months Ended |
12 Months Ended |
0 Months Ended |
1 Months Ended |
|
Dec. 31, 2013
|
Dec. 31, 2014
|
Sep. 30, 2014
|
Jun. 30, 2014
|
Mar. 31, 2014
|
Dec. 31, 2013
|
Sep. 30, 2013
|
Jun. 30, 2013
|
Mar. 31, 2013
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Feb. 17, 2012
|
Apr. 30, 2014
|
Jan. 31, 2015
|
Jul. 31, 2014
|
Sep. 30, 2014
|
Dec. 31, 2014
|
| Restricted cash |
$ 0us-gaap_RestrictedCashAndCashEquivalentsNoncurrent |
$ 5,405,600,000us-gaap_RestrictedCashAndCashEquivalentsNoncurrent |
|
|
|
$ 0us-gaap_RestrictedCashAndCashEquivalentsNoncurrent |
|
|
|
$ 5,405,600,000us-gaap_RestrictedCashAndCashEquivalentsNoncurrent |
$ 0us-gaap_RestrictedCashAndCashEquivalentsNoncurrent |
|
|
|
|
|
|
$ 5,405,600,000us-gaap_RestrictedCashAndCashEquivalentsNoncurrent |
| Acquired in-process research and development |
57,100,000lly_AcquiredInProcessResearchAndDevelopment |
105,200,000lly_AcquiredInProcessResearchAndDevelopment |
95,000,000lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
57,100,000lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
200,200,000lly_AcquiredInProcessResearchAndDevelopment |
57,100,000lly_AcquiredInProcessResearchAndDevelopment |
0lly_AcquiredInProcessResearchAndDevelopment |
|
|
|
|
|
|
| Payments to Acquire Businesses, Net of Cash Acquired |
|
|
|
|
|
|
|
|
|
551,400,000us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired |
43,700,000us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired |
199,300,000us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired |
|
|
|
|
|
|
| Goodwill |
1,516,800,000us-gaap_Goodwill |
1,758,100,000us-gaap_Goodwill |
|
|
|
1,516,800,000us-gaap_Goodwill |
|
|
|
1,758,100,000us-gaap_Goodwill |
1,516,800,000us-gaap_Goodwill |
|
|
|
|
|
|
1,758,100,000us-gaap_Goodwill |
| ChemGen [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination, Consideration Transferred |
|
|
|
|
|
|
|
|
|
|
|
|
206,900,000us-gaap_BusinessCombinationConsiderationTransferred1 / us-gaap_BusinessAcquisitionAxis = lly_ChemgenMember |
|
|
|
|
|
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |
|
|
|
|
|
|
|
|
|
|
|
|
151,500,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles / us-gaap_BusinessAcquisitionAxis = lly_ChemgenMember |
|
|
|
|
|
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net |
|
|
|
|
|
|
|
|
|
|
|
|
55,400,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet / us-gaap_BusinessAcquisitionAxis = lly_ChemgenMember |
|
|
|
|
|
| Lohmann Animal Health [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination, Consideration Transferred |
|
|
|
|
|
|
|
|
|
|
|
|
|
591,200,000us-gaap_BusinessCombinationConsiderationTransferred1 / us-gaap_BusinessAcquisitionAxis = lly_LohmannAnimalHealthMember |
|
|
|
|
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net |
|
|
|
|
|
|
|
|
|
|
|
|
|
51,100,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet / us-gaap_BusinessAcquisitionAxis = lly_LohmannAnimalHealthMember |
|
|
|
|
| Payments to Acquire Businesses, Net of Cash Acquired |
|
|
|
|
|
|
|
|
|
|
|
|
|
551,400,000us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired / us-gaap_BusinessAcquisitionAxis = lly_LohmannAnimalHealthMember |
|
|
|
|
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
39,800,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt / us-gaap_BusinessAcquisitionAxis = lly_LohmannAnimalHealthMember |
|
|
|
|
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment |
|
|
|
|
|
|
|
|
|
|
|
|
|
89,800,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment / us-gaap_BusinessAcquisitionAxis = lly_LohmannAnimalHealthMember |
|
|
|
|
| Goodwill |
|
|
|
|
|
|
|
|
|
|
|
|
|
243,700,000us-gaap_Goodwill / us-gaap_BusinessAcquisitionAxis = lly_LohmannAnimalHealthMember |
|
|
|
|
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent |
|
|
|
|
|
|
|
|
|
|
|
|
|
92,700,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent / us-gaap_BusinessAcquisitionAxis = lly_LohmannAnimalHealthMember |
|
|
|
|
| Novartis Animal Health [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Acquisition, Pro Forma Revenue |
|
|
|
|
|
|
|
|
|
20,700,000,000us-gaap_BusinessAcquisitionsProFormaRevenue / us-gaap_BusinessAcquisitionAxis = lly_NovartisAnimalHealthMember |
|
|
|
|
|
|
|
|
| Novartis Animal Health [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination, Consideration Transferred |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,400,000,000us-gaap_BusinessCombinationConsiderationTransferred1 / us-gaap_BusinessAcquisitionAxis = lly_NovartisAnimalHealthMember / us-gaap_SubsequentEventTypeAxis = us-gaap_SubsequentEventMember |
|
|
|
| Immunocore Limited [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acquired in-process research and development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45,000,000lly_AcquiredInProcessResearchAndDevelopment / us-gaap_BusinessAcquisitionAxis = lly_ImmunocoreLimitedMember |
|
|
| AstraZeneca [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acquired in-process research and development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000,000lly_AcquiredInProcessResearchAndDevelopment / us-gaap_BusinessAcquisitionAxis = lly_AstraZenecaMember |
|
| Adocia [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acquired in-process research and development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000,000lly_AcquiredInProcessResearchAndDevelopment / us-gaap_BusinessAcquisitionAxis = lly_AdociaMember |
| Developed Technology Rights [Member] | Lohmann Animal Health [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |
|
|
|
|
|
|
|
|
|
|
|
|
|
275,400,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles / us-gaap_BusinessAcquisitionAxis = lly_LohmannAnimalHealthMember / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_DevelopedTechnologyRightsMember |
|
|
|
|
| Customer Relationships [Member] | Lohmann Animal Health [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |
|
|
|
|
|
|
|
|
|
|
|
|
|
23,900,000us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles / us-gaap_BusinessAcquisitionAxis = lly_LohmannAnimalHealthMember / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis = us-gaap_CustomerRelationshipsMember |
|
|
|
|
| United States [Member] | U.S. Sentinel Product Line [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from Divestiture of Businesses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 410,000,000us-gaap_ProceedsFromDivestitureOfBusinesses / us-gaap_ProductOrServiceAxis = lly_U.S.SentinelProductLineMember / us-gaap_StatementGeographicalAxis = country_US / us-gaap_SubsequentEventTypeAxis = us-gaap_SubsequentEventMember |
|
|
|